Mylan Pharmaceuticals has lost its bid in D.C. federal court to force a Food and Drug Administration decision on whether a rival company can have exclusive rights to sell the generic version of Lipitor.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *